ArticleAngiogenesis2012
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
Article in Angiogenesis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 484 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 0 Study to Evaluate the Pharmacokinetics of Low-dose Bevacizumab and Its Efficacy on Reducing Plasma Free Vascular Endothelial Growth Factor-A (VEGF-A) in Hemodialysis Patients
Subconjunctival Aflibercept Injection for Pseudophakic Cystoid Macular Edema
Who cites it
484 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,024 citations in OpenAlex.
- The efficacy and safety of anti-vascular endothelial growth factor combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) · 2021Pooled it
- A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.International journal of clinical oncology · 2025Trial
- Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema.Translational vision science & technology · 2024Trial
- Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration.Scientific reports · 2024Trial
- Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.Eye (London, England) · 2024Trial
- Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Trial
- Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.Health technology assessment (Winchester, England) · 2021Trial
- Molecular Determinants of Intravitreal Anti-VEGF Durability: Drug Architecture, Intraocular Pharmacokinetics, Target Biology and Treatment Resistance.International journal of molecular sciences · 2026Review
- Comparative Histopathological Effects of Intra-Articular Bevacizumab, Ranibizumab, and Aflibercept in Experimental Osteoarthritis.Journal of clinical medicine · 2026Article
- Correlation between aqueous humour cytokine and imaging biomarker in Central Retinal Vein Occlusion-Macular Edema.BMC ophthalmology · 2026Article
- Choroidal Changes after Intravitreal Aflibercept, Faricimab, Brolucizumab, and High-Dose Aflibercept in Treatment-Naïve Neovascular Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- Therapeutic Plasma Exchange for Removal of Bevacizumab: A Case Series.Journal of clinical apheresis · 2026Article
- Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results.Cell reports. Medicine · 2026Article
- An Overview and Trend Analysis of Biosimilar Approvals in China.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Understanding anti-vascular endothelial growth factor medications: chemical properties, costs, and side effects.Journal of medicine and life · 2026Review
- Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.Eye (London, England) · 2026Review
- Inhibition of VEGFJournal of chemical information and modeling · 2026Article
- Anti-vascular endothelial growth factors in retinal and choroidal diseases - Present landscape.Indian journal of ophthalmology · 2026Review
- Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead.Indian journal of ophthalmology · 2026Review
424 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.